KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Non Operating Income (2018 - 2025)

Esperion Therapeutics (ESPR) has disclosed Non Operating Income for 8 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Income fell 10.94% year-over-year to $1.1 million, compared with a TTM value of $3.5 million through Dec 2025, down 56.49%, and an annual FY2025 reading of $3.5 million, down 56.49% over the prior year.
  • Non Operating Income was $1.1 million for Q4 2025 at Esperion Therapeutics, up from $677000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $3.9 million in Q4 2021 and bottomed at $9000.0 in Q2 2021.
  • Average Non Operating Income over 5 years is $1.2 million, with a median of $1.1 million recorded in 2023.
  • Peak annual rise in Non Operating Income hit 16312.5% in 2021, while the deepest fall reached 96.2% in 2021.
  • Year by year, Non Operating Income stood at $3.9 million in 2021, then crashed by 65.6% to $1.4 million in 2022, then dropped by 20.3% to $1.1 million in 2023, then increased by 11.76% to $1.2 million in 2024, then fell by 10.94% to $1.1 million in 2025.
  • Business Quant data shows Non Operating Income for ESPR at $1.1 million in Q4 2025, $677000.0 in Q3 2025, and $666000.0 in Q2 2025.